Dr. Goel brings over 25 years of experience in immunology and drug development to the company, having previously held senior roles at Formation Bio, Abcuro, and Kezar Life Sciences. Her clinical background, which includes an appointment as an Adjunct Assistant Professor at Duke University School of Medicine, will be central to the development of HST-2011. This small molecule inhibitor targets IRF5, a transcription factor identified as a master regulator of innate immunity and a key driver in diseases such as systemic lupus erythematosus and Sjögren's disease.

CEO Jonathan Montagu stated that Goel’s expertise is essential for navigating the transition of the company’s Smart Allostery platform toward late-stage clinical programs. The company recently designated HST-2011 as its primary development candidate, aiming to provide a once-daily oral treatment option. By targeting naturally occurring regulatory pockets on proteins, HotSpot seeks to bypass the limitations of traditional drug discovery methods, focusing specifically on inflammatory and immune system disorders.